{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:36:17Z","timestamp":1789670177930,"version":"4.0.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Treatment-resistant obsessive-compulsive disorder (OCD) remains a major clinical challenge, with a substantial proportion of patients failing to respond to standard treatment with selective serotonin reuptake inhibitors (SSRI). Vortioxetine, a multimodal antidepressant approved for major depressive disorder, has shown potential advantages in terms of tolerability and cognitive enhancement, but its efficacy in OCD has not been systematically explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter, retrospective, observational study analyzed the clinical records of 64 adult patients with a DSM-5 diagnosis of OCD who had failed to respond to at least one adequate SSRI trial and were treated with vortioxetine monotherapy (minimum dose: 20 mg\/day; duration: \u22658 weeks). The primary outcome was reduction in total Y-BOCS score. Secondary outcomes included changes in HAM-D and HAM-A scores and frequency of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 8, 39.1% of patients met responder criteria (\u226525% reduction in total Y-BOCS score). The mean Y-BOCS score decreased from 27.1 to 20.7 (p &amp;lt; 0.001). HAM-D and HAM-A scores showed significant improvements (HAM-D: from 21.0 to 12.6; HAM-A: from 26.9 to 16.1; both p &amp;lt; 0.001). The treatment was well tolerated, with nausea (29.7%) and sedation (18.8%) being the most common side effects; no serious adverse events occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides preliminary evidence of the efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD. The observed improvements in OCD, depressive and anxiety symptoms suggest that vortioxetine may represent a valuable therapeutic option. Further prospective controlled trials are needed to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1617345","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:49:33Z","timestamp":1749793773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD: a retrospective multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Vassilis","family":"Martiadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Ignazio","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzurra","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Raffone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Prodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Olivola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Benatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Maria","family":"Dell\u2019Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"B1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S187048","article-title":"Multidisciplinary approaches to the treatment of obsessive\u2013compulsive disorder: Current perspectives","volume":"15","author":"Fineberg","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000137","article-title":"Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive\u2013compulsive disorder","volume":"31","author":"Benatti","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2014.05.006","article-title":"Pharmacological treatment of obsessive-compulsive disorder","volume":"37","author":"Pittenger","year":"2014","journal-title":"Psychiatr Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.04.068","article-title":"Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis","volume":"218","author":"Sugarman","year":"2017","journal-title":"J Affect Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","article-title":"Response rates for CBT for anxiety disorders: Need for standardized criteria","volume":"42","author":"Loerinc","year":"2015","journal-title":"Clin Psychol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/157340005774575028","article-title":"Antipsychotics in obsessive-compulsive disorder","volume":"1","author":"Maina","year":"2000","journal-title":"Curr Psychiatry Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"152352","DOI":"10.1016\/j.comppsych.2022.152352","article-title":"Treatment-resistant OCD: pharmacotherapies in adults","volume":"120","author":"Van Roessel","year":"2023","journal-title":"Compr Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2082525","article-title":"Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a network meta-analysis of randomized controlled trials","volume":"24","author":"Suhas","year":"2023","journal-title":"World J Biol Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.12.009","article-title":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis","volume":"90","author":"Zhou","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD008141","DOI":"10.1002\/14651858.CD008141.pub2","article-title":"Second-generation antipsychotics for obsessive compulsive disorder","volume":"12","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000348","article-title":"Serotonin reuptake inhibitors augmentation with cariprazine in patients with treatment-resistant obsessive-compulsive disorder: a retrospective observational study","volume":"22","author":"Martiadis","year":"2024","journal-title":"CNS Spectr"},{"key":"B15","first-page":"396","article-title":"Brexpiprazole augmentation in treatment resistant OCD: safety and efficacy in an Italian sample","volume":"36","author":"Martiadis","year":"2024","journal-title":"Psychiatr Danub"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000583","article-title":"Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study","author":"Giacovelli","year":"2025","journal-title":"Int Clin Psychopharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.914493","article-title":"An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder","volume":"15","author":"Pizarro","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyac054","article-title":"Effect of vortioxetine on cognitive impairment in patients with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Huang","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyw081","article-title":"The bioRx model of vortioxetine","volume":"20","author":"Millan","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852914000662","article-title":"The neuropsychology of obsessive-compulsive personality disorder: a new analysis","volume":"20","author":"Fineberg","year":"2015","journal-title":"CNS Spectr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale: Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.12.003","article-title":"Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults","volume":"227","author":"Fineberg","year":"2015","journal-title":"Psychiatry Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12991-024-00526-w","article-title":"Effectiveness of 8-week treatment with vortioxetine on depressive symptoms in major depressive disorder patients with comorbid generalized anxiety disorder in UAE (TRUE)","volume":"23","author":"Badr","year":"2024","journal-title":"Ann Gen Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221090627","article-title":"Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study","volume":"36","author":"Christensen","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116118","article-title":"The dose-response relationship of vortioxetine on major depressive disorder: an umbrella review","volume":"340","author":"Wang","year":"2024","journal-title":"Psychiatry Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.074","article-title":"Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability","volume":"328","author":"Adair","year":"2023","journal-title":"J Affect Disord"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01824-z","article-title":"Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis","volume":"28","author":"Kishi","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20299","article-title":"Towards an international expert consensus for defining treatment response, remission, recovery, and relapse in obsessive\u2013compulsive disorder","volume":"15","author":"Mataix-Cols","year":"2016","journal-title":"World Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1617345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:49:34Z","timestamp":1749793774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1617345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":33,"alternative-id":["10.3389\/fpsyt.2025.1617345"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1617345","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"article-number":"1617345"}}